Arvinas, a biotech company specializing in targeted protein degradation drugs, will present its first quarter 2026 financial results and provide a corporate update on May 12, 2026, via a live webcast. The company is known for developing the first FDA-approved PROTAC drug, VEPPANU, for advanced breast cancer, and is advancing several investigational drugs for neurodegenerative diseases and cancers. Investors and interested parties can access the webcast on Arvinas' website, with a replay available after the event. This update is important as it offers insights into the company's progress and financial health amid ongoing drug development.
The 32nd Global Family Office Investment Summit in Lake Como gathered over 200 family office leaders, investors, and entrepreneurs from 27 countries to discuss emerging trends in AI, private equity, healthcare innovation, and global investment opport...
Bath & Body Works introduced Fruit Fusion, a new body care franchise featuring fruit-inspired scents and hydrating formulas, available in the U.S. and Canada starting July 6, 2026. Actress Hilary Duff serves as the brand ambassador and creative partn...
Prestige Consumer Healthcare completed the acquisition of Australian therapeutic skin care company LaCorium Health for approximately $150 million in cash on July 1, 2026. LaCorium, known for brands like Dermal Therapy and Flexitol, generates about $4...
GuideAI Health Corp. has appointed Dr. James F. Benenati, a leading interventional radiologist, to its Advisory Board following FDA 510(k) clearance of its AI software, VascularAssist Occlusion Triage (VAOT). VAOT is designed to help radiologists pri...
Diginex Limited has agreed with Resulticks to extend the deadline for their acquisition deal to July 31, 2026, after securing firm funding intent from private investors. The company does not plan to seek public funding and expects this to be the fina...
